図３ 基本的な GWAS の研究デザイン
ヒトで行われる GWAS は基本的に単一の人種につい D A B C
L E T T E R S
ering the vast majority of the canine genome (< 2% of overage), although the MHC and chromosome X have . In previous studies, proof-of-principle mapping of ic traits in canines have been performed, identifying r white coat color 3 and many other traits [14] [15] [16] . we demonstrate the power of the dog for mapping . By analyzing 81 cases (37 with IMRD, of which 22 sitivity, and 44 with SRMA) and 57 controls, we idenate loci on chromosomes 3, 8, 11, 24 and 32 through of either 'all cases together', 'ANA-positive IMRD only'. The initial P-values were in the range of three loci reached genome-wide significance-P value corrected for genome-wide search by permutaome = 0.02, ANA-positive IMRD only)), chromosome .04, ANA-positive IMRD only) and chromosome .04, SRMA only)-after correction for stratification of permutation testing to correct for multiple hypoig. 1, Table 1 and Supplementary Fig. 1 ). The MHC eviously identified by a candidate gene approach 11 , d in this study, probably owing to lack of sufficient SNP array in that region of the genome. ping, we included additional NSDTRs for a total of h IMRD, of which 32 showed ANA positivity, 78 with controls; nine dogs were classified as having both A). Data were analyzed in three groups: dataset 1 in GWA, n = 138), dataset 2 (additional dogs includiduals, n = 186) and as a combined dataset (datasets . Three loci (chromosomes 3, 11 and 24) were very ed, with P values of 10 −11 -10 −13 for the combined nd Table 1 ) and with supportive P values for datasets ly (10 −4 -10 −11 ; Table 1 ). These loci all predispose to phenotype of ANA-positive IMRD disease and show .5-8. These odds ratios are relatively strong and fall e previously predicted to be detectable with roughly 0 controls 1 . The other two loci (chromosomes 8 and r P values of only 10 −5 -10 −8 in the fine-mapping with weaker odds ratios of 2.4-3.4. Although the convincing, the sample sizes in this study are small iable detection of risk factors contributing a two-to ed risk cannot be expected. Still, these relative risks are r most human complex traits. These loci also show a attern of association to the different subphenotypes. e 32 locus shows association in SRMA and ANAseparately and together, but there is also evidence of cross a large 1.6-Mb region, making the interpreplicated (Fig. 3) . In the ANA-positive IMRD-only , one can potentially discern three associations, one ee excellent candidate genes (DAPP1, PPP3CA and 1 encodes a B-cell-specific scaffold protein and LYN substrate that promotes tyrosine phosphorylation of sphosphate receptors, and has already been associated LE 17 . Similarly, the chromosome 8 locus shows RMA and ANA-positive IMRD disease separately ( Supplementary Fig. 2 ). It is therefore unclear whether these loci carry one uniform risk factor for multiple diseases or multiple risk factors. Still, we consider all five loci as good candidates to contribute to this disease complex and therefore worthy of follow-up.
The associated regions contain excellent candidate genes based on biological function, although several of the regions are large enough to contain multiple genes, making it difficult to determine which are causative. Nonetheless, some striking patterns surrounding T-cell activation emerge (Fig. 4) , which might form a plausible connection between this form of SLE-related disease and the survival of a small number of NSDTR dogs from the expansive canine distemper virus outbreaks that savaged the breed in the early 1900s 7 . In addition, current breeding practices within this dog breed also contribute to the enrichment of certain risk factors.
Three regions contain genes involved in T-cell activation through the nuclear factor of activated T cells (NF-AT) pathway. The chromosome 32 region contains the PPP3CA gene, which encodes the catalytic subunit of calcineurin, alpha isoform 18 . Calcineurin is a well-known target of two important immunosuppressive drugs (cyclosporine A 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0 3 1 3 2 3 3 3 4 3 5 3 6 3 7 3 8 X 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0 3 1 3 2 3 3 3 4 3 5 3 6 3 7 3 8 X 
図４ 全身性エリテマトーデスの GWAS の結果（Ａ-Ｃ）と想定されるメカニズム（Ｄ） （Wilbe ら 2010） （Ａ）全疾患個体を用いた GWAS の結果。 （Ｂ） 免疫介在性リウマチを呈する個体のみを疾患群とした場合 の GWAS の結果。 （Ｃ）ステロイド反応性髄膜炎-動脈炎を呈する個体のみを疾患群とした場合の GWAS の結果。 （Ｄ）GWAS の結果から想定されるメカニズム。GWAS によって同定された領域に存在する遺伝子 には＊を付加した。

